CDH1 and Peutz-Jeghers syndrome: Patients who have mutations in genes including TP53, BRCA1, BRCA2, CDH1, PALB2, ATM, or have an inherited syndrome such as Peutz-Jeghers syndrome, PTEN, Hamartoma tumor syndromes, Neurofibromatosis type 1 are at a higher risk of developing malignancy, so this cohort of patients may need an earlier qualification for biopsy or removal of the lesion (34).